Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
15.93
+0.13 (0.82%)
At close: Aug 1, 2025, 4:00 PM
15.92
-0.01 (-0.06%)
After-hours: Aug 1, 2025, 7:32 PM EDT
Model N Revenue
Arrowhead Pharmaceuticals had revenue of $542.71M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $545.21M, up 1,436.97% year-over-year. In the fiscal year ending September 30, 2024, Arrowhead Pharmaceuticals had annual revenue of $3.55M, down -98.52%.
Revenue (ttm)
$545.21M
Revenue Growth
+1,436.97%
P/S Ratio
3.70
Revenue / Employee
$895,253
Employees
609
Market Cap
2.20B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ARWR News
- 1 day ago - Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Business Wire
- 5 days ago - Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Business Wire
- 8 days ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 10 days ago - Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics - Business Wire
- 10 days ago - How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals - Seeking Alpha
- 11 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results - Business Wire
- 25 days ago - Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire